• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Prazosin for Alcohol Use Disorders

Prazosin for Alcohol Use Disorders

February 1, 2019
Michael Posternak, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Simpson TL et al, Am J Psych 2018; https://doi.org/10.1176/appi.ajp.2018.17080913

TYPE OF STUDY: Randomized, placebo-controlled trial

Prazosin is often used as a second-line option for a broad array of psychiatric conditions, including anxiety, insomnia, nightmares, and post-traumatic stress dis­order (PTSD). It is a high blood pressure medication that also modulates the stress-response system through noradrenergic effects, blocking alpha-1 receptors in the brain. Since stress is a common trigger for excessive drinking, this study set out to test whether prazosin could improve so­briety in alcohol use disorders.

Eighty subjects with alcohol use disorders were randomized to receive either prazosin or placebo. Subjects with PTSD were excluded in order to isolate the potential benefits of prazo­sin for drinking directly. Prazosin was titrated up to a target dosage of 16 mg/ day, as tolerated. All subjects were ac­tively drinking at the start of the study, and they reported their daily alcohol consumption and cravings for the pre­vious day through a toll-free interactive voice system during the 12-week study. Assessments were double-blind, and the primary outcomes were: (1) number of drinks per week, (2) number of drink­ing days per week, and (3) number of heavy drinking days per week.

Compared to placebo, those re­ceiving prazosin reported fewer drinks (mean decrease of 8.0 vs 1.5 drinks per week; p = 0.03) and fewer number of heavy drinking days (mean decrease of 0.8 vs 0.3 days per week; p = 0.01), though the number of drinking days was no less with prazosin. Drowsiness and edema were the only two side ef­fects associated with prazosin.

TCPR’S Take
Given its relatively benign side effect pro­file and established track record, prazosin can already be considered a reasonable second-line option for alcohol use disor­ders. For patients with any combination of anxiety, insomnia, nightmares, PTSD, or hypertension, prazosin is an even more appealing option.
General Psychiatry
KEYWORDS research-update
    Michael Posternak, MD.

    Psychological Benefits of Abstaining from Social Media

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Dark and Light Therapy, TCPR, February 2019
    An Opioid Combo Falls Short in Depression
    Prazosin for Alcohol Use Disorders
    Does Mania Follow the Sun?
    CBT for Insomnia
    Light and Darkness in Bipolar Disorder
    Trintellix and Cognition: A Closer Look
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.